Abstract
Liver cancer affects a significant number of individuals annually, and it ranks as the third leading cause of cancer-related deaths. In the past decade, significant advances have been brought to provide more options for treating hepatocellular carcinoma (HCC). However, the development of treatment resistance in HCC patients raises challenges for clinicians in managing this malignant tumor. The use of the CRISPR/Cas9 system to identify genes that enhance clinical response in HCC patients lays a solid foundation for personalized treatment. This article summarizes the current understanding of using the CRISPR/Cas9 system in cancer therapy, particularly emphasizing its application to HCC. This review presents examples and relative mechanisms of using CRISPR/Cas9 with immune checkpoint inhibitors to control tumor cell growth and discusses how CRISPR/Cas9 can prevent viral hepatitis from progressing to HCC. This review aims to improve patient prognosis and fundamentally transform the treatment landscape of HCC by reviewing the prospects and current status of CRISPR technology in the treatment of HCC
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call